



ASX ANNOUNCEMENT

Lumos Appoints Henry Schein as US Distributor for FebriDx®

MELBOURNE, Australia (12 February 2024) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, has signed an agreement with Henry Schein, Inc. (Nasdaq: HSIC) to distribute FebriDx® in the United States (US).

FebriDx is a rapid point-of-care respiratory test which delivers results 10 minutes from a fingerstick blood sample. In July 2023, the US Food and Drug Administration cleared FebriDx to be marketed in the US as an aid in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology. The test has been cleared for use by healthcare professionals with patients presenting in urgent care or emergency care settings and is intended to be used in conjunction with clinical signs and symptoms, including other clinical and laboratory findings, to evaluate patients for acute respiratory infection.

Henry Schein, the world’s largest provider of health care solutions to office-based dental and medical practitioners, currently distributes the FebriDx test in the UK, Spain, Portugal, and the Netherlands. By expanding reach of this product in the US, Henry Schein can enhance its current diagnostic offering to US customers, which are supported by Henry Schein’s dedicated Lab Services team, comprised of specialists throughout the country. In collaboration with its diagnostic partners, Henry Schein’s diagnostic testing portfolio includes molecular tests, rapid antigen tests, and rapid antibody tests.

*“We are delighted that Henry Schein has expanded its distribution coverage for our FebriDx test to include the United States,” said **Doug Ward, CEO and Managing Director** of Lumos Diagnostics. “The US is the biggest commercial opportunity for FebriDx due to the routine use of point-of-care tests in standard clinical workflow and established reimbursement. We believe FebriDx has a unique role in ensuring that antibiotics are only given to patients who are likely to benefit from them. As Henry Schein has been an excellent distribution partner for Lumos in Europe, we are very excited to have them as our distribution partner in the world’s largest market for point-of-care testing”.*

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Haley Chartres – Australia
HACK Director
haley@hck.digital
+61 423 139 163

Investor Contact:

Jane Lowe
Managing Director, IR Department
ir@lumosdiagnostics.com
+61 411 117 774

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205, Australia
+61 3 9087 1598